Results 321 to 330 of about 143,709 (342)
Some of the next articles are maybe not open access.
CD3/CD20/CD45 negative leukemia cutis
Journal of HematopathologyA 56-year-old male presented to the clinic with complaints of multiple skin lesions. A complete blood count (CBC) was not available. No constitutional symptoms were present, and physical examination revealed tender skin lesions of the back, arms, legs, and scalp. A skin punch biopsy showed fragments of skin with extensive lymphoid infiltrates.
Ilya, Tsvetnov +2 more
openaire +2 more sources
CD20 antibodies: doing the time warp
Blood, 2011With the success of the anti-CD20 mAb rituximab in treating B-cell disorders from lymphoma through rheumatoid arthritis, anti-CD20 mAbs are now big business with as many as 16 biosimilars in clinical development. 1 Understanding what makes CD20 such an ideal target and how to select new anti-CD20 mAbs is the subject of intense research.
openaire +2 more sources
La Presse Médicale, 2009
Points essentiels Cela fait 12 ans que le rituximab, anticorps (Ac) monoclonal chimerique anti-CD20 a ete mis a disposition pour une utilisation therapeutique dans le traitement des lymphomes folliculaires en rechute. Cet Ac a permis de gagner environ 20 % de survie dans la quasi-totalite des lymphomes B .
openaire +1 more source
Points essentiels Cela fait 12 ans que le rituximab, anticorps (Ac) monoclonal chimerique anti-CD20 a ete mis a disposition pour une utilisation therapeutique dans le traitement des lymphomes folliculaires en rechute. Cet Ac a permis de gagner environ 20 % de survie dans la quasi-totalite des lymphomes B .
openaire +1 more source
International MS journal, 2008
Immune modulators, such as interferon beta and glatiramer acetate, have focused on T-cells as the primary therapeutic target, although both drugs affect other cell types as well. There has been a renewed interest in the potential roles of both antibody-dependent and antibody-independent B-cell responses in multiple sclerosis (MS) and its animal model ...
openaire +1 more source
Immune modulators, such as interferon beta and glatiramer acetate, have focused on T-cells as the primary therapeutic target, although both drugs affect other cell types as well. There has been a renewed interest in the potential roles of both antibody-dependent and antibody-independent B-cell responses in multiple sclerosis (MS) and its animal model ...
openaire +1 more source
Journal of biological regulators and homeostatic agents, 2003
P J, Macardle, I C, Nicholson
openaire +1 more source
P J, Macardle, I C, Nicholson
openaire +1 more source